The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer

Pannek, Jürgen; Subong, Eric N.P.; Jones, Kerrie A.; Marschke, Penny; Epstein, Jonathan I.; Chan, Daniel W.; Carter, H. Ballentine; Luderer, Albert A.; Partin, Alan W.

doi:10.1016/s0090-4295(96)00610-3

Cited by 56 publications

(26 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pannek et al, 30 using the same free PSA and total PSA assays as used in this study, found similarly high variations in percent-free PSA values across different pathologic stages of tumors removed from 301 men. Bangma et al 31 used a different assay system and showed no difference in percent-free PSA between organ-confined and extraprostatic tumors in 49 patients treated by radical prostatectomy.…”

Section: Discussionsupporting

confidence: 66%

Serum Percent–Free PSA Does Not Predict Extraprostatic Spread of Prostate Cancer

et al. 1998

View full text Add to dashboard Cite

Percent-free prostate-specific antigen (proportion of free prostate-specific antigen [PSA] to total PSA) has been shown recently in studies on frozen serum samples to be more useful than total PSA alone in distinguishing prostate cancer from benign conditions of the prostate gland. The primary purpose of our study was to determine whether percent-free PSA could predict extraprostatic spread of prostate cancer. We also sought to evaluate the freeze-thaw stability of free PSA. Percent-free PSA values in fresh serum samples were compared with those in aliquots subjected to one to five freeze-thaw cycles. Percent-free PSA values in frozen serum samples from 130 men undergoing Prostate-specific antigen (PSA) is a 33-kd serine protease secreted almost exclusively by prostatic columnar epithelial cells.1 Serum PSA is the best and most widely used tumor marker for the early diagnosis and m a n a g e m e n t of prostate cancer.2 -5 Another major use of PSA is monitoring for recurrence in patients after radical prostatectomy; a detectable serum PSA value is a most sensitive indicator of residual or recurrent disease. 6 ' 7 PSA has proven to be less useful in preoperative staging of clinically localized prostatic adenocarcinoma,

show abstract

Section: Discussionsupporting

confidence: 66%

Serum Percent–Free PSA Does Not Predict Extraprostatic Spread of Prostate Cancer

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Percent-free PSA also failed to predict the pathologic stage of the tumors and was only weakly correlated to the Gleason score. These results are consistent with the findings of other groups, 13,14 indicating that percent-free PSA provides no additional information for staging prostate cancer.…”

Section: American Journal Of Clinical Pathologysupporting

confidence: 92%

Free Prostate-Specific Antigen:Does It Measure Up?

Schreiber

1998

Am J Clin Pathol

View full text Add to dashboard Cite

“…The calculation of a PSA index is also only valid when the constituent PSA concentrations are derived from matched assays with the same calibration, 126 and the t-PSA assay has an equimolar response. 95 This is supported by the differing opinions expressed by Pannek et al, 127,128 who found no association between PSA index values and clinical stage when using unrelated assays from two separate manufacturers, 127 but a signi®cant association when using matched assays from a single manufacturer. 128 Similar indices can be derived from c-PSA and t-PSA, with equal clinical effect, 129,130 although it has been suggested that the assay of c-PSA alone will give similar diagnostic potential at lower operational cost.…”

Section: Psa Indexmentioning

confidence: 97%

Prostate specific antigen: biology, biochemistry and available commercial assays

Ward

Catto²,

Hamdy³

2001

Ann Clin Biochem

131

108

View full text Add to dashboard Cite

Prostate speci®c antigen (PSA) is the marker of choice in the management of prostate cancer. However, PSA is not a simple molecule, existing in the serum in ®ve isoforms and a number of molecular con®gurations and complexes. The elucidation of the biochemistry of PSA has increased the potential use of the marker in the diagnosis of prostate malignancy.This review summarizes the clinical use of PSA in the management of prostate disease and the assays available in the UK. Assay calibration in relation to the World Health Organization 1st International Standard for Prostate Speci®c Antigen (90:10) has increased conformity between the various commercial assay kits, and the nonequimolar kits have largely been superseded or withdrawn. Special reference is made to evaluations performed on behalf of the Medical Devices Agency of the Department of Health.

show abstract

The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer

Cited by 56 publications

References 8 publications

Serum Percent–Free PSA Does Not Predict Extraprostatic Spread of Prostate Cancer

Serum Percent–Free PSA Does Not Predict Extraprostatic Spread of Prostate Cancer

Free Prostate-Specific Antigen:Does It Measure Up?

Prostate specific antigen: biology, biochemistry and available commercial assays

Contact Info

Product

Resources

About